Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

NCT03697512 is registered in ClinicalTrials.gov with International Extranodal Lymphoma Study Group (IELSG) as lead sponsor.

NCT NCT03697512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03697512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Lead sponsor
International Extranodal Lymphoma Study Group (IELSG)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 27, 2019
Completion date
June 15, 2027
Enrollment
175 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma, nodal marginal zone lymphoma, splenic marginal zone lymphoma